Heparan sulfate domains on cultured activated glomerular endothelial cells mediate leukocyte trafficking  by Rops, A.L. et al.
Heparan sulfate domains on cultured activated
glomerular endothelial cells mediate leukocyte
trafficking
AL Rops1, MJ van den Hoven1, MM Baselmans1, JF Lensen2, TJ Wijnhoven2,3, LP van den Heuvel3,
TH van Kuppevelt2, JH Berden1 and J van der Vlag1
1Nephrology Research Laboratory, Nijmegen Centre for Molecular Life Sciences, Division of Nephrology, Radboud University Nijmegen
Medical Centre, Nijmegen, The Netherlands; 2Department of Matrix Biochemistry, Nijmegen Centre for Molecular Life Sciences, Radboud
University Nijmegen Medical Centre, Nijmegen, The Netherlands and 3Department of Pediatrics, Radboud University Nijmegen Medical
Centre, Nijmegen, The Netherlands
Heparan sulfate (HS) proteoglycans by playing key roles in
the leukocyte–endothelial interactions are thought to
mediate inflammatory cell influx in proliferative
glomerulonephritis. Here, we evaluated the specific features
within glomerular endothelial HS that promote leukocyte
adhesion. Mouse and human glomerular endothelial cells
activated by tumor necrosis factor (TNF)-a or interleukin
(IL)-1b increased expression of inflammatory N- and 6-O-
sulfated HS domains. In addition, altered expression of
HS-modifying enzymes occurred, a feature also found in
mouse kidneys with anti-glomerular basement membrane
disease or lupus nephritis. Inhibition of the nuclear factor
(NF)-jB pathway repressed cytokine-induced alterations in
HS and gene expression of modifying enzymes. Firm
adhesion of leukocytes to activated mouse glomerular
endothelial cells decreased after removal of endothelial HS
or addition of sulfated heparinoids. Specific antibodies that
block N- and 6-O-sulfated HS domains on activated mouse
endothelial cells reduced the number of rolling and firmly
adhering leukocytes under dynamic flow conditions, while
they increased the average leukocyte-rolling velocity. Our
study shows that N- and 6-O-sulfated domains in HS on
activated glomerular endothelium are crucial for leukocyte
trafficking and are possible therapeutic targets.
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Proliferative glomerulonephritis is manifested in a range of
diseases and characterized by the influx of inflammatory cells
(leukocytes). Leukocyte–endothelium interactions are a
central event in inflammation in general, and leukocyte
trafficking to/on/through activated endothelium can be
divided into four sequential steps, that is, leukocyte tethering,
rolling, firm adhesion, and transmigration, respectively.1,2
Heparan sulfate proteoglycans (HSPGs) play an important
role in all these steps.3–5
HSPGs are expressed in a tissue- and stage-specific
manner at the surface of virtual all cells and in the
extracellular matrix. HSPGs consist of a core protein with
linear covalently attached heparan sulfate (HS) sugar side
chains, which belong to the family of strongly negatively
charged glycosaminoglycans (GAGs) that also includes
heparin and non-sulfated hyaluronan. HSPGs are involved
in many biologic processes such as cell adhesion, migration,
proliferation, and differentiation, which are mediated by
the binding of chemokines, cytokines, enzymes, and growth
factors to HS.3,6,7 The HS chain consists of up to 150
a(1–4)-glucuronate-b(1–4)-N-acetyl-glucosamine disaccharide
units that can be modified extensively. Modification of HS
starts with N-deacetylation and N-sulfation of N-acetyl-
glucosamine catalyzed by four different N-deacetylase/
N-sulfotransferase isoenzymes. Subsequently, C-5 epimerization
of glucuronate to iduronate catalyzed by C5-epimerase, and
O-sulfation at various positions (C-2, C-3, and C-6) catalyzed
by al large family of sulfotransferases may occur.6 The structure
of HS chains may be further edited by HS-modifying enzymes
such as heparanase, a b(1–4)-endoglucuronidase that cleaves
HS at specific sites,8,9 and HS 6-O-endosulfatases (Sulf-1 and
Sulf-2) that specifically remove 6-O-sulfate.10,11 Due to the
combination of possible modifications, HS is characterized by
an enormous structural diversity, in particular in sulfation
patterns, which is important for the specific binding and
modulation of a wide range of factors corresponding to the
different biologic activities of HS.6,12
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The role of HS in the different steps of leukocyte
trafficking is recently reviewed.3–5 In brief, tethering of leuko-
cytes involves binding of chemokines to HS at the surface of
endothelial cells and in the extracellular matrix.13,14 Rolling
of leukocytes is mediated by L-selectin expressed by leuko-
cytes and P-selectin expressed by endothelial cells. HS can
serve as a ligand for both L- and P-selectin.15–22 Firm adhe-
sion of leukocytes involves interactions between integrins,
like Mac-1 and integrin ligands, such as endothelial HS.22,23
Transmigration of leukocytes also involves HS-binding
factors, like heparin-binding protein, while GAGs can influence
this process.22,24 Notably, heparanase expressed by activated
endothelial cells and leukocytes degrades HS in the inflamed
area, thus facilitating transmigration of leukocytes.25,26
HS isolated from different (microvascular) endothelial cells
shows distinct sulfation patterns, which implies differences in
HS structure–function relationships including its role in the
leukocyte–endothelium interaction.3,4,27–29 The HS domains
on glomerular endothelial cells that promote the rolling and
firm adhesion of leukocytes remain elusive. This knowledge
could lead to the development of well-defined supplementary
HS-based therapeutics with anti-inflammatory effects. There-
fore, we evaluated the features within glomerular endothelial
HS that are important for the rolling and/or the firm adhesion
of leukocytes using various approaches.
RESULTS
Expression of HS (PGs) by unstimulated and activated
glomerular endothelial cells and the involvement of nuclear
factor-jB
Expression of the HSPG core proteins syndecan-1, syndecan-
4, glypican-1, CD44, and endostatin/collagen XVIII (Table 1)
was significantly upregulated after activation of the mouse
glomerular endothelial cell line (mGEnC)-1 with tumor
necrosis factor (TNF)-a or interleukin (IL)-1b, while glypi-
can-3, agrin, and perlecan (Table 1) were hardly expressed
(Figure 1a). The amount of HS expressed by mGEnC-1, as
estimated by heparinase III treatment followed by 3G10
staining, increased B2-fold after activation with TNF-a
(Figure 1b) or IL-1b (Figure S1). Anti-HS antibodies recog-
nizing distinct structural features within HS, which include
sulfation of various residues and epimerization of glucuronate
(Table 2), were used to characterize the structural features of
HS on mGEnC-1. The reactivity of the anti-HS antibody 10E4,
which recognizes a N-sulfated/N-acetylated HS domain,37
increased B1.5-fold after activation with TNF-a (Figure 1b)
or IL-1b (Figure S1). In addition, the reactivities of AO4B08,
EW3D10, and EW4G2, which all recognize N- and 6-O-
sulfated HS domains (Table 2), increased B1.5- to 2.5-fold
after activation. The reactivities of EV3B2, HS3A8, HS4C3,
and LKIV69, which recognize N- and/or 2-O-sulfated HS
domains (Table 2), decreased B1.5-fold after activation.
Finally, the reactivities of HS4E4 and RB4Ea12, which recog-
nize N-sulfated domains, did not change upon activation.
Similar results were obtained with primary human glomerular
endothelial cells (hGEnC) after activation with TNF-a (Figure
1c). The nuclear factor (NF)-kB pathway may mediate the
cytokine-induced activation of endothelial cells.38,39 To get a
clue about the mechanisms underlying cytokine-induced
changes in glomerular endothelial HS structure and function,
the canonical or the non-canonical NF-kB pathway was
inhibited with BAY-110782 and calcitriol, respectively. BAY-
110782 completely prevented alterations in HS on mGEnC-1
activated with TNF-a (Figure 1b) or IL-1b (Figure S1),
whereas BAY-110782 had no effect on the expression of HS by
unstimulated mGEnC-1 (data not shown). Inhibition of the
non-canonical NF-kB pathway had no effect on cytokine-
induced HS alterations on mGEnC-1 (data not shown). An
altered expression profile of HS-modifying enzymes could
explain the increased expression of N- and 6-O-sulfated HS
domains by activated mGEnC-1. Indeed, mRNA expression of
N-deacetylase/N-sulfotransferase-1 and -2, and 6-O-sulfo-
transferase-1 and -2 increased about 2-fold after activation
with TNF-a, while the mRNA expression of 6-O-sulfatase-2
Table 1 | Details on the primary and secondary antibodies used in this study
Antigen/specificity Antibody Source/reference Dilution Secondary antibody
Syndecan-1 281–2 BD Biosciences 200 Goat anti-rat IgG Alexa 488a
Syndecan-4 KY/8.2 BD Biosciences 100 Goat anti-rat IgG Alexa 488
Glypican-1 N-16 Santa Cruz Biotechnology,
Santa Cruz, CA, USA
10 Rabbit anti-goat IgG Alexa 488
Glypican-3 G-16 Santa Cruz Biotechnology 10 Rabbit anti-goat IgG Alexa 488
Endostatin/collagen XVIII Enst11-S Alpha Diagnostics International,
San Antonio, TX, USA
50 Goat anti-rabbit IgG Alexa 488
CD44 IM7 BD Biosciences 100 Goat anti-rat IgG Alexa 488
Agrin core Bl31 Van den Heuvel et al.30 400 Goat anti-rabbit IgG Alexa 488
Agrin N-terminus MI91 Raats et al.31 800 Goat anti-hamster IgG FITCb
Perlecan EY90 Hassell et al.32 8000 Goat anti-rabbit IgG Alexa 488
HS: N-acetylated and N-sulfated units 10E4 Seikagaku Corporation 100 Goat anti-mouse IgM Alexa 488
HS: 4,5-unsaturated uronate residues 3G10 Seikagaku Corporation 100 Goat anti-mouse IgM Alexa 488
L-selectin MEL-14 BD Biosciences 50 Goat anti-rat IgG Alexa 488
Mac-1 MI70 ATCC, Manassas, VA, USA 1 Goat anti-rat IgG Alexa 488
Heparanase HPA1 ProsPec-Tany, Rehovot, Israel 100 Goat anti-rabbit IgG Alexa 488
aAll Alexa-conjugated antibodies were from Invitrogen (Breda, The Netherlands). Dilution 1:200.
bCappel, Turnhout, Belgium. Dilution 1:400.
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decreased about 4-fold (Table 3). The expression of the other
evaluated HS-modifying enzymes was not detectable. Inhibi-
tion of the canonical NF-kB pathway prevented the TNF-a-
induced alterations in mRNA expression of HS-modifying
enzymes (Table 3). Cells activated with IL-1b yielded
essentially the same results (data not shown). The cytokine-
induced mRNA expression of ICAM-1, included as a control
for endothelial activation, was also inhibited by BAY-110782.
Recently, we described a significantly increased expression of
the inflammatory N- and 6-O-sulfated HS domains, which
are defined by the anti-HS antibodies EW3D10, AO4B08, and
EW4G2, on glomerular endothelium in human and murine
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Figure 1 | Expression of HSPG core proteins and different HS domains by unstimulated and activated glomerular endothelial cells,
and the involvement of NF-kB. (a) The expression of HSPG core proteins and different HS structures by unstimulated and TNF-a- or
IL-1b-activated mGEnC-1 was measured by flow cytometry. Relative mean fluorescence intensity (MFI; upper panel) and percentage positive
cells (lower panel) are shown. The MFI of unstimulated mGEnC-1 cells is set at 100. Staining by 3G10 was performed after heparinase III
treatment. *Po0.05 versus unstimulated mGEnC-1 (n¼ 5). (b) The expression of several HS domains recognized by anti-HS antibodies
(Table 2) was measured by flow cytometry in unstimulated mGEnC-1, mGEnC-1 activated with TNF-a and mGEnC-1 activated with TNF-a
in the presence of BAY-110782, an inhibitor of the canonical NF-kB pathway. *Po0.05 versus unstimulated mGEnC-1. ^Po0.05 versus
activated mGEnC-1 (n¼ 5). (c) The expression of syndecan-1 and -4, and several HS domains recognized by anti-HS antibodies (Table 2)
was measured by flow cytometry in unstimulated and TNF-a-activated hGEnC. The MFI of unstimulated hGEnC is set at 100. *Po0.05
versus unstimulated hGEnC (n¼ 5). Sc-1, syndecan-1; Sc-4, syndecan-4; Glp-1, glypican-1; Glp-3, glypican-3; Endst, endostatin/collagen XVIII.
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lupus nephritis40 and during experimental anti-glomerular
basement membrane (GBM) nephritis.41 Therefore, we also
evaluated the expression of HS-modifying enzymes in the
renal cortex of mice with experimental anti-GBM nephritis
or lupus nephritis. This revealed in the nephritic mice aB2-
fold increased expression of N-deacetylase/N-sulfotransfer-
ase-1 and -2, and 6-O-sulfotransferase-1 and -2, while the
expression of 6-O-sulfatase-2 decreased B2-fold (Table 4).
The expression of ICAM-1, which was used as control for
activated endothelium, was also increased in nephritic mice.
Taken together, activation of glomerular endothelial cells
with TNF-a or IL-1b leads to an increased HS (PG) expres-
sion and structural HS alterations that include N- and 6-O-
sulfated HS domains, which are also found in vivo. These HS
changes are accompanied with an altered expression of the
relevant HS-modifying enzymes both in vivo and in vitro.
Furthermore, the canonical NF-kB pathway mediates cyto-
kine-induced changes in glomerular endothelial HS.
Enhanced release of HS enriched in N- and 6-O-sulfated
domains in the cell culture supernatant of activated
glomerular endothelial cells is associated with an increased
heparanase expression
A 2-fold increase of sulfated HS in the culture supernatant of
mGEnC-1 activated with TNF-a or IL-1b was measured
biochemically. Expression of the HS-hydrolyzing enzyme
heparanase by mGEnC-1 increased B2-fold after activation
with TNF-a or IL-1b (Figure 2a; Table 3) and could serve as a
possible explanation for the presence of HS in the culture
supernatant.25,26,42 Primary human glomerular endothelial
cells (Figure 2a) and HUVEC (data not shown) also showed
an increased expression of heparanase after activation with
TNF-a or IL-1b. Furthermore, in the renal cortex of nephritic
mice the mRNA heparanase expression wasB10-fold increa-
sed compared to the corresponding control mice (Table 4).
The features of the released HS were evaluated by using anti-
HS antibodies. The reactivity of the majority of the anti-HS
antibodies with released HS was hardly affected by activation,
while the reactivity of 10E4, AO4B08, EW3D10, and EW4G2
increased B2- to 6-fold after activation with TNF-a (Figure
2b) or IL-1b (Figure S2). Furthermore, inhibition of the
canonical NF-kB pathway prevented the release of HS
enriched in N- and 6-O-sulfated domains by mGEnC-1
activated with TNF-a or IL-1b, and the upregulation of
heparanase (Figure 2b; Figure S2; Table 3). These data show
that HS released by activated glomerular endothelial cells
is enriched in specific N- and 6-O-sulfated domains, which
is mediated by the canonical NF-kB pathway.
HS on activated mGEnC-1 is crucial for the firm adhesion
of leukocytes
The role of GAGs on mGEnC-1 in the firm adhesion of
leukocytes was evaluated in an in vitro static adhesion
system with the granulocyte cell line 32Dcl3, which expresses
L-selectin, Mac-1, LFA-1, and NIMP-R14,43,44 primary
Table 4 | Gene expression profile of HS-modifying enzymes in
renal cortex of mice with glomerulonephritis
Relative expression
Mice
Target gene Anti-GBMa MRL/lprb
N-deacetylase/N-sulfotransferase-1 1.95 1.48
N-deacetylase/N-sulfotransferase-2 2.15 1.49
6-O-sulfotransferase-1 2.19 1.51
6-O-sulfotransferase-2 1.73 4.46
6-O-sulfatase-2 0.45 0.37
Heparanase 10.4 13.9
ICAM-1 22.2 5.02
aThe expression in mice (n=3) induced with anti-GBM nephritis (8 days after the
induction of disease) is relative to the expression in untreated C57bl/6 mice (n=3)
that is set at 1.
bThe expression in 22-week-old MRL/lpr mice with lupus nephritis (n=3) is relative to
the expression in age-matched MRL+/+ (n=3) mice that is set at 1. Expression is
quantified by the d–d Ct method using GAPDH as a reference gene. ICAM-1,
intercellular adhesion molecule-1 was used as a marker for endothelial activation.
Table 2 | Structural features of the epitopes of anti-GAG
antibodiesa
Antibody
HS/CS moieties required
for antibody binding
10E4 GlcA-GlcNS-GlcA-GlcNAc
AO4B08 GlcNS6S-IdoA2S
EV3B2 GlcNS76S-GlcA/IdoA
EW3D10 GlcNS6S
EW4G2 GlcNS6S-GlcA
HS3A8 GlcNS6S-IdoA2S
HS4C3 GlcNS3S6S-GlcA/IdoA2S
HS4E4 GlcNAc/GlcNS-IdoA
LKIV69 GlcNS-IdoA2S
RB4Ea12 IdoA-GlcNS6S
IO3H10 GlcA2S-GalNAc4S6S
aCS, chondroitin sulfate; GAG, glycosaminoglycan; GalNAc, N-acetylated-galactosa-
mine; GlcA, glucuronate; GlcNAc, N-acetylated-glucosamine; GlcNS, N-sulfated-
glucosamine; HS, heparan sulfate; IdoA, iduronate; S, sulfate.33–36
Table 3 | Gene expression profile of HS-modifying enzymes in
unstimulated and activated mGEnC-1 and the effect of
inhibiting the canonical NF-jB pathwaya
Relative expression
Activated
Target gene Unstimulated BAY +BAY
N-deacetylase/N-sulfotransferase-1 1 2.7 0.97
N-deacetylase/N-sulfotransferase-2 1 1.5 0.94
N-deacetylase/N-sulfotransferase-3 — — —
N-deacetylase/N-sulfotransferase-4 — — —
6-O-sulfotransferase-1 1 1.7 0.95
6-O-sulfotransferase-2 1 2.0 1.05
6-O-sulfotransferase-3 — — —
6-O-sulfatase-1 — — —
6-O-sulfatase-2 1 0.29 0.96
Heparanase 1 2.17 0.93
ICAM-1 1 51 1.3
BAY, BAY-110782; ICAM-1, intercellular adhesion molecule-1.
—: not detectable (Ct440).
aThe expression is relative to the expression in unstimulated cells that is set at 1 and
is quantified by the d–d Ct method using GAPDH as a reference gene.
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granulocytes, and the monocyte cell line WEHI 274.1.45 In
contrast to primary granulocytes and WEHI 274.1 cells,
32Dcl3 cells lack HS, which makes them suitable to delineate
the role of endothelial HS in leukocyte/granulocyte adhesion.
The adhesion of 32Dcl3 cells, primary mouse granulocytes
or WEHI 274.1 cells increased about B4- to 5-fold after
activation of mGEnC-1 with TNF-a (Figure 3) or IL-1b
(Figure S3). The removal of endothelial HS by heparinase III
reduced adhesion B2-fold, while removal of chondroitin
sulfate (CS)/dermatan sulfate (DS) by chondroitinase ABC
had no effect (Figure 3 and Figure S3). Additional heparinase
III treatment of primary granulocytes or WEHI 274.1 cells
led to a reduced binding of only B10% (data not shown).
Inhibition of the canonical NF-kB pathway completely
prevented the enhanced binding of leukocytes to mGEnC-1
activated with TNF-a (Figure 3) or IL-1b (Figure S3), which
indicates that the expression of non-HS inflammatory
adhesion molecules is also regulated by NF-kB signaling.
In summary, HS expressed by activated mGEnC-1 is crucial
for the firm adhesion of leukocytes, whereas HS on these
leukocytes is less important. Furthermore, the enhanced
binding of leukocytes to activated mGEnC-1 depends on the
canonical NF-kB pathway.
GAGs, heparinoids, anti-HS antibodies, and HS from cell
culture supernatant of activated mGEnC-1 can inhibit the
firm adhesion of 32Dcl3 cells to activated mGEnC-1
The effect of different GAGs, heparinoids (Figure 4; Table 5)
and anti-HS antibodies (Table 2) on the firm adhesion of
32Dcl3 cells to activated mGEnC-1 was tested under static
conditions. Adhesion of 32Dcl3 cells was B40% reduced by
the addition of HS, while CS, the non-sulfated HS hyaluronic
acid, and heparosan (K5) had no effect (Figure 5a). However,
chemically O-sulfated heparosan significantly reduced adhe-
sion. Heparin reduced adhesion B2-fold (Figure 5b),
whereas the inhibitory effects of modified heparinoids
increased in this order: O-desulfated heparino6-O-desul-
fated heparin or N-desulfated heparino2-O-desulfated
heparin (Figure 5b). Testing of clinically applied low
molecular weight (LMW) heparins revealed that tinzaparin
and enoxaparin inhibited adhesion most efficiently (Figure
5b). Notably, tinzaparin and enoxaparin have the highest
degree of N-sulfated and 6-O-sulfated residues of the
analyzed LMW heparins (Table 5). Blocking of endothelial
HS structures on activated mGEnC-1 with specific anti-HS
antibodies (Table 2) revealed that EW4G2, EW3D10, and
AO4B08 were the most potent inhibitory antibodies (Figure
5c). These antibodies preferentially bind to specific N- and
6-O-sulfated HS domains (Table 2), which were also upregu-
lated at the cell surface and enriched in the culture
HS in cell culture supernatant (AU)
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Figure 2 | Heparanase expression and release of HS in cell culture
supernatant by unstimulated and activated glomerular
endothelial cells. (a) The protein expression of heparanase by
unstimulated, TNF-a-activated or IL-1b-activated mGEnC-1 or primary
hGEnC. About 100% of both unstimulated and activated mGEnC-1
and hGEnC expressed heparanase (not shown). The mean
fluorescence intensity (MFI) of unstimulated mGEnC-1 or hGEnC is set
at 1. *Po0.01 versus unstimulated mGEnC-1 or hGEnC, respectively
(n¼ 5). (b) HS in culture supernatant of unstimulated mGEnC-1,
TNF-a-activated mGEnC-1, and TNF-a-activated mGEnC-1 in the
presence of BAY-110782. HS was measured by an inhibition ELISA.
Plates coated with HS from bovine kidney were incubated with
the depicted anti-HS antibodies (Table 2) that had been preincubated
with culture supernatant from either unstimulated or TNF-a-activated
mGEnC-1, either in the presence or absence of BAY-110782. The
results are expressed as mean7s.e.m. *Po0.01 versus unstimulated
mGEnC-1. ^Po0.01 versus activated mGEnC-1 (n¼ 5). AU: arbitrary
units (‘mg ml1’).
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Figure 3 | HS plays an important role during firm adhesion of
leukocytes to activated mGEnC-1. Monolayers of mGEnC-1 either
unstimulated or activated with TNF-a were treated with heparinase
III, chondroitinase ABC, or BAY-110782 as indicated. Subsequently,
labeled 32Dcl3 cells (granulocyte cell line), primary granulocytes,
or WEHI 274.1 cells (monocyte cell line) were added. Percentage
adhesion of leukocytes to activated mGEnC-1 is set at 100%.
*Po0.001 versus activated mGEnC-1. Experiments were performed
in triplicate (n¼ 5).
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supernatant of activated mGEnC-1 (Figures 1b, c, and 2b).
Therefore, the effect of cell culture supernatants of mGEnC-1
on adhesion was determined. Adhesion was reducedB2-fold
by cell culture supernatant from mGEnC-1 activated with
TNF-a (Figure 6) or IL-1b (Figure S4). Heparinase III
treatment of the culture supernatant abolished this inhibitory
effect, indicating that HS was responsible for the inhibition.
Culture supernatant of unstimulated mGEnC-1 was not able
to inhibit the adhesion. To exclude that the released HS was
a result of apoptosis, we analyzed Annexin V/PI staining
of unstimulated and TNF-a-activated mGEnC-1. The rate of
apoptosis did not exceed background values, and there were
no differences between activated and unstimulated mGEnC-1
(data not shown). Furthermore, cell culture supernatants of
mGEnC-1 activated with cytokines and treated with BAY-
110782 completely failed to inhibit granulocyte adhesion
(Figure 6; Figure S4). Taken together, specific N- and 6-O-
sulfated HS domains on activated glomerular endothelial
cells are crucial for the firm adhesion of leukocytes, while the
released HS enriched in the same HS domains is able to
modulate leukocyte adhesion. The canonical NF-kB pathway
is an important mediator in these processes.
Blocking of the inflammatory sulfated HS domains on
glomerular endothelium interferes with the rolling and firm
adhesion of 32Dcl3 cells under flow conditions
The adhesion data described in the previous section were
obtained under static adhesion conditions and only address
the firm adhesion of leukocytes. Therefore, we recently
developed a dynamic flow system to evaluate leukocyte
adhesion under flow conditions, which mimics the in vivo
situation. We showed that removal of HS on TNF-a-activated
mGEnC-1 and the addition of heparin, tinzaparin, or HS
largely reduced the number of rolling and firmly adhering
32Dcl3 cells under flow conditions.47 Here, we evaluated
under dynamic flow conditions the effects of addition of the
anti-HS antibodies EW3D10 and AO4B08, which bind to the
specific inflammatory N- and 6-O-sulfated HS domains, on
leukocyte trafficking on activated glomerular endothelium.
Addition of EW3D10 or AO4B08 reduced the number of
rolling and firmly adhering 32Dcl3 cells B2-fold (Figure 7a
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Table 5 | Characteristics of LMW heparins46a
Trisulfated
disaccharides (AU)
Disulfated
disaccharides (AU)
Monosulfated
disaccharide (AU)
Generic drug name
(Brand name; manufacturer) Composition
Molecular weight
(kDa) 2SNS6S NS3S6S NS6S 2SNS 6S
Heparin (Sigma-Aldrich) Heparin 5–30 34.7 1.2 4.0 1.6 0.9
Dalteparin (Fragmin; Pharmacia, Woerden,
The Netherlands)
LMW heparin 4–6 49.3 2.6 3.2 3.1 2.0
Enoxaparin (Clexane; Sanofi-Aventis,
Gouda, The Netherlands)
LMW heparin 3.5–5.5 71.3 1.9 11.4 2.5 1.4
Tinzaparin (Innohep; Brocacef Holding,
Maarssen, The Netherlands)
LMW heparin 3.4–5.6 88.9 1.9 7.5 5.4 1.4
Danaparoid (Orgaran; Organon, Oss,
The Netherlands)
HS/DS/CS (84/12/
4%)
4–10 — — — — —
Sulodexide (Vessel Due F;
Alfa Wassermann, S.P.A., Bologna, Italy)
80% fast-moving
heparin, 20% DS
o8 — — — — —
Nadroparin (Fraxiparin; Sanofi-Aventis) LMW heparin 2.4–7.2 17.2 0.8 1.2 1.8 0.7
Fondaparinux (Arixtra; Sanofi-Aventis) Pentasaccharide
(C31H43N3Na10S8)
1.728 — — — — —
aAU, arbitrary unit; CS, chondroitin sulfate; DS, dermatan sulfate; HS, heparan sulfate; LMW, low molecular weight; NS, N-sulfate; 2S, 2-O-sulfate; 3S, 3-O-sulfate; 6S, 6-O-sulfate;
—, not analyzed.
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and b), whereas the average rolling velocity increased B2-
fold (Figure 7c). It appears that the inhibitory effects of the
anti-HS antibodies are even more pronounced under
dynamic flow conditions than under static conditions
(compare Figures 5c and 7). Taking these data together, the
inflammatory HS domains on glomerular endothelium that
are defined by the anti-HS antibodies EW3D10 or AO4B08,
and which are also observed in (experimental) glomerulone-
phritis in vivo, are of functional importance in the rolling and
firm adhesion of leukocytes on glomerular endothelium.
DISCUSSION
Previously, an increased expression of the HSPG core
proteins syndecan-1, syndecan-4, and CD44 by activated
endothelial cells from other vascular beds has been shown,
while other HSPG core proteins were not evaluated.3,5 An
explicit role of the core proteins in inflammatory leukocyte
trafficking is not established and may only be determined by
the attached HS side chains.18,19 We observed both an
increased and structurally altered HS expression by mGEnC-
1 after activation with cytokines. Several anti-HS antibodies
that recognize N- and 6-O-sulfated HS domains showed an
enhanced reactivity with activated mGEnC-1 and human
glomerular endothelial cells. These antibodies most likely
require next to N- and 6-O-sulfation other features for
binding, that is, the exact localization of these sulfate groups
in a specific HS context, and elucidation of the complete
epitopes remains a major future challenge.33–36
The altered expression profile of HS-modifying enzymes
upon activation of in vitro cultured glomerular endothelial
cells explains the increased expression of specific N- and 6-O-
sulfated HS domains. Recently, we also showed an increased
glomerular endothelial expression of the inflammatory
N- and 6-O-sulfated HS domains in lupus mice and SLE
patients,40 and in experimental anti-GBM nephritis.41 We
now show that also in vivo, in experimental glomerulo-
nephritis, there is an altered expression profile of HS-modifying
enzymes similar to the data obtained in vitro with activated
*
>200
>200
>200
IC25 in µg ml–1:
75
36
*
0 10 20 30 40 50
Heparan sulfate
O -sulfated
heparosan
Heparosan
Chondroitin sulfate
Hyaluronic acid
0 10 20 30 40 50 60
Tinzaparin
Enoxaparin
Danaparoid
Dalteparin
Nadroparin
Sulodexide
Fondaparinux
6-O -desulfated H
2-O -desulfated H
O -desulfated H
N-desulfated H
Heparin c
&a,b
‡b
a,b
b
#c
#c
18
>200
>200
18
>200
>200
200
200
90
32
10
11
^
0 10 20 30 40
RB4Ea12
LKIV69
HS4E4
HS4C3
HS3A8
EW4G2
EW3D10
EV3B2
AO4B08
% inhibition
TNF-α
IL-1β
^^^
^
^
^
^
^
Figure 5 | Inhibitory capacity of sulfated GAGs, heparinoids, and
anti-HS antibodies on firm adhesion of 32Dcl3 cells to activated
mGEnC-1. Monolayers of mGEnC-1 activated with TNF-a were
co-incubated with labeled 32Dcl3 cells and (a) various GAGs and
(b) heparinoids. Monolayers of mGEnC-1 activated with TNF-a or
IL-1b were co-incubated with labeled 32Dcl3 cells and (c) anti-HS
antibodies (Table 2). The percentage inhibition of adhesion is
calculated by the formula ((100X)/100 100%), in which X is the
relative adhesion compared to the control without addition
(adhesion of 32Dcl3 cells without addition to activated mGEnC-1 is
set at 100%). The concentrations giving 25% inhibition (IC25) in
mg ml1 are indicated. All anti-HS antibodies were used at 25 mg ml1.
(a) *Po0.01 versus control without GAGs. (b) &a,bPo0.01 versus
O-desulfated H (a, b); zbPo0.01 versus 6-O-desulfated H (b),
N-desulfated H, and O-desulfated H (a, b); #cPo0.01 versus heparin
(c). (c) ^Po0.05 versus control without antibody. Experiments were
performed in triplicate (n¼ 5). H, heparin.
HepIII treatment of culture sup:
Culture sup HS (TNF-α+BAY):
%
 re
la
tiv
e 
ad
he
sio
n
0
20
40
60
80
100
Culture sup HS (TNF-α):
– + +
+ +
+
+ +
–
–
–
–
–
–
–
–
–
– – +
TNF-α:
*
Figure 6 | Inhibitory effect of released HS on adhesion of 32Dcl3
cells to activated mGEnC-1. A monolayer of activated mGEnC-1
was co-incubated with 32Dcl3 cells and conditioned medium from
TNF-a-activated mGEnC-1 (designated ‘culture sup HS (TNF-a)’),
either in the absence or presence of BAY-110782 (designated ‘culture
sup HS (TNF-aþ BAY)’). Where indicated the conditioned medium
was treated with heparinase III. Adhesion of 32Dcl3 cells without
addition to activated mGEnC-1 is set at 100%. Experiments were
performed in triplicate (n¼ 4). *Po0.01 versus activated mGEnC-1
without addition.
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cultured glomerular endothelial cells. The pronounced
decrease in expression of 6-O-sulfatase-2 is of interest, since
both 6-O-sulfatase-1 and -2 also play an important role in HS
editing in other biologic processes.10,11 Importantly, we could
demonstrate in vitro that cytokine-induced alterations of
glomerular endothelial HS and HS-modifying enzymes are
mediated by the canonical NF-kB pathway, which is also
involved in the regulation of expression of other inflamma-
tory molecules on activated endothelial cells.38,39 Our
findings are in agreement with the increased synthesis of
HS by activated primary bovine glomerular endothelial cells
and the increased expression of N-sulfated HS on activated
human microvascular cells, which was also associated with an
increased N-deacetylase/N-sulfotransferase-1 expression.14,48
The release of HS in the culture supernatant from acti-
vated mGEnC-1 has also been described for activated bovine
glomerular endothelial cells.48 Our analysis of the features of
the released HS revealed enrichment in N- and 6-O-sulfated
HS domains. The release of HS can be explained by the
increased expression of the HS-degrading enzyme hepar-
anase, which cleaves off cell surface HS.42,49 Heparanase
cleaves the b(1–4) bond within HS and the proposed cleavage
site for heparanase requires N- and 6-O-sulfated moieties in
a specific context.8,9 Therefore, the enrichment of N- and
O-sulfated domains in cell surface endothelial HS after
activation could make the HS chains more susceptible to
cleavage by heparanase.
The importance of endothelial HS for the adhesion of
leukocytes is well established, whereas leukocyte HS also
plays a role in this process.3–5 We showed that, in particular,
glomerular endothelial HS was important for rolling and
adhesion of leukocytes (this work).47 Recently, a conditional
endothelial/leukocyte-specific mouse knockout for N-deace-
tylase/N-sulfotransferase-1 has been established, which
showed a reduced leukocyte influx in experimental perito-
nitis.22 Transfer of wild-type bone marrow into this mouse
did not lead to a restoration of leukocyte influx, which
underscores that especially endothelial HS is important for
leukocyte adhesion as we confirm with our current data.
Finally, we showed that removal of HS from activated
mGEnC-1 did not reduce the adhesion of leukocytes
completely, which indicates that in addition to HS-dependent
interactions, HS-independent interactions also play a role.
Apparently, receptors on leukocytes require specific
N- and 6-O-sulfated HS domains on activated mGEnC-1
for firm adhesion under static conditions as revealed by
the inhibitory effect of defined GAGs, heparinoids, LMW
heparins, and anti-HS antibodies, which in part has been
described for other endothelial cells.21,50 Recently, we have
shown that heparin, LMW heparins, and HS also interfere
with the leukocyte–mGEnC-1 interaction under dynamic
flow conditions, which mimics the in vivo situation more
realistically than a static adhesion assay.47 We now show
that the blocking of N- and 6-O-sulfated HS domains
on activated mGEnC-1, with specific anti-HS antibodies
strongly reduced the number of rolling and firmly adhering
leukocytes, while the average leukocyte rolling velocity
increased. These results suggest that the inflammatory
HS domains may be functional in vivo as well. Ligands
on leukocytes, such as the integrin Mac-1 and L-selectin, may
serve as potential receptors for the inflammatory N- and
6-O-sulfated HS domains on activated mGEnC-1. Other
reports also describe the importance of both N- and 6-O-
sulfation for the leukocyte–endothelium interaction.4,19,21–23
The HS released in the cell culture supernatant of activated
mGEnC-1 contained the same N- and 6-O-sulfated domains
as HS on the cell surface of activated mGEnC-1, which
explains the inhibitory capacity of cell culture supernatant
in leukocyte adhesion. The released HS may have an anti-
inflammatory role under normal physiological conditions
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Figure 7 | Blocking of inflammatory N- and 6-O-sulfated HS
domains on endothelium with specific anti-HS antibodies
strongly reduces the number of rolling and firmly adhering
leukocytes under dynamic flow conditions. Granulocyte cells
(32Dcl3 cells) were perfused at a shear stress rate of 0.8 dyne cm2
over a monolayer of mGEnC-1 activated with TNF-a in the absence or
presence of specific anti-HS antibodies (25mg ml1) AO4B08 or
EW3D10, which both define inflammatory N- and 6-O-sulfated HS
domains on glomerular endothelium. The average number7s.e.m. of
rolling cells (a), the average number of firmly adhering cells (b), and
the average rolling velocity (c) were determined in duplicate in three
independent experiments. *Po0.05 versus TNF-a-activated mGEnC-1
without addition.
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or in the early phases of inflammation by binding to recep-
tors like L-selectin and Mac-1, which prevents premature
leukocyte adhesion.
In conclusion, using several approaches, we demonstrated
that N- and 6-O-sulfated HS domains on activated
glomerular endothelial cells are crucial for the rolling and
firm binding of leukocytes. These cytokine-induced changes
in glomerular endothelial HS are mediated by the canonical
NF-kB pathway. A challenge will be to determine the exact
structure of the inflammatory HS domains, which may be
achieved by partially digesting HS from activated glomerular
endothelium, followed by affinity purification with functional
ligands like Mac-1 and L-selectin, then followed by HS
disaccharide analysis and mass spectrometry analysis.51 We
have proven that the inflammatory N- and 6-O-sulfated HS
domains are present on activated glomerular endothelium both
in vitro and in vivo, and are functional in vitro in leukocyte
trafficking. But we have not provided formal proof yet that
these specific HS domains are also functional in vivo in
leukocyte trafficking during glomerulonephritis. To this end, we
plan to induce experimental glomerulonephritis in mice with a
targeted disruption of genes encoding HS-modifying enzymes
followed by analysis of glomerular leukocyte influx, as has been
recently described for other inflammatory models.22 Since
leukocyte infiltration is important in the formation of
glomerular inflammatory lesions, further characterization of
the glomerular endothelial HS structures that play a role in the
leukocyte–endothelium trafficking is of prime importance. This
may lead to the development of selective well-defined HS-based
analogues as supplementary therapeutic strategies in treating
glomerulonephritis.12
MATERIALS AND METHODS
Cell culture and treatment with GAG-degrading enzymes
Conditionally immortalized mGEnC-1 cells with all features of
primary glomerular endothelial cells were cultured as described.52
Primary human glomerular endothelial cells and HUVEC were
isolated and propagated as described.53 Cells were activated with
TNF-a (10 ng ml1; Peprotech, Rocky Hill, NJ, USA) or IL-1b
(10 ng ml1; Peprotech) for 18 h. Where indicated, BAY-110782
(7.5 mM; Tebu-Bio, Heerhugowaard, The Netherlands) or calcitriol
(10 nM; Tebu-Bio), inhibitors of the canonical and the non-
canonical NF-kB pathway, respectively, were added. The murine
granulocyte cell line 32Dcl3 and monocyte cell line WEHI 274.1
were cultured as described.43,44,54 Primary mouse granulocytes were
isolated using a gelatin sponge.55 HS was removed by treatment with
0.25 U ml1 heparinase III (Sigma-Aldrich, Zwijndrecht, The
Netherlands) for 1 h at 371C. The terminal 4,5-unsaturated uronate
residues that arise after heparinase III treatment are recognized
by antibody 3G10,37 which was used to evaluate enzyme activity.
CS/DS was removed by treating with 1 U ml1 chondroitinase
ABC (Sigma-Aldrich) for 1 h at 371C. The activity of chondroitinase
ABC was checked with the anti-CS antibody IO3H10.33
Animals
Anti-GBM nephritis was induced in C57bl/6 mice (Jackson
Laboratories, Bar Habor, ME, USA) by i.v. injection of 8 mg purified
rabbit anti-mouse GBM IgG, essentially as described.41 Animals were
killed after 8 days and kidneys were snap-frozen in liquid nitrogen.
Age-matched untreated C57bl/6 mice served as controls. Diseased
proteinuric MRL/lpr (Jackson Laboratories) mice were killed at an
age of 22 weeks. Age-matched MRLþ /þ (Jackson Laboratories)
mice served as controls. Animals were housed and handled
according to the guidelines of the Local Animal Ethics Committee.
Flow cytometry
Cells were detached with 10 mM EDTA and washed with PBS. Cells
were incubated with primary antibody (Table 1) in PBA (PBS
containing 0.5% BSA; Sigma-Aldrich) for 30 min and subsequently
washed in PBA. Appropriate Alexa-/FITC-labeled antibodies
(Table 1) were used for detection, while anti-HS scFv antibodies
(Table 2) were detected by an anti-VSV antibody (clone P5D4;
Sigma-Aldrich) followed by an Alexa-labeled antibody. All detecting
antibodies were incubated in PBA for 30 min. Subsequently, cells
were washed and resuspended in PBA. Heparanase expression was
measured using Fix and Perm reagents (Sanbio, Uden, The
Netherlands). Fluorescence was measured using a FACScan (Becton
Dickinson, San Jose, CA, USA).
RNA isolation and real-time reversed transcription-PCR
RNA was isolated using the RNeasy Mini protocol, including a DNase
I step (Qiagen, Venlo, The Netherlands). Reversed transcription of
1mg RNA was performed with Oligo dT primers and the Superscript
First-Strand Synthesis System (Invitrogen Life Technologies, Breda,
The Netherlands). One-tenth of cDNA was used as template in real-
time PCR using SYBR Green Supermix (Bio-Rad, Veenendaal, The
Netherlands) with gene-specific primers (10mM; Biolegio, Malden,
The Netherlands; Table 6) on the MyiQ PCR system (Bio-Rad).
Determination of the structural features of HS released in cell
culture supernatants of mGEnC-1 by an inhibition ELISA
Flat bottom 96-well plates (Nunc A/S, Roskilde, Denmark) were
coated with 5 mg well1 HS from bovine kidney (Seikagaku
Table 6 | Primers used in real-time PCR
Target gene Primer sequence (50-30)
N-deacetylase/N- (F) GAGCGATGCATCCTCAAAGCTGCGTG
sulfotransferase-1 (R) GATCGTAATCCTTTAGGAAG
N-deacetylase/N- (F) GAGCCCCTCTGCTACTTCGCT
sulfotransferase-2 (R) GATCTGGCTGGCCAAGCCGAC
N-deacetylase/N- (F) TGTGTTTCCTGTGAGTCCAGATGTGTG
sulfotransferase-3 (R) ATTGTCCTCCTCACTTCCATCAGCCTG
N-deacetylase/N- (F) GGACTTTTTCCCCAC
sulfotransferase-4 (R) TTTAAATCAGGAGGGGCCC
6-O-sulfotransferase-1 (F) CGCCCAGAAAGTTCTACTACATC
(R) GGTTGTTAGCCAGGTTATAGGG
6-O-sulfotransferase-2 (F) TCCTTCAGACCCATTTCC
(R) CCCACACACAGCATAACAC
6-O-sulfotransferase-3 (F) TGAATGAGAGCGAGCGGAAC
(R) CCAAAGTAATCCAAGAGAAG
6-O-sulfatase-1 (F) CCACCTCTCCCTTCTTGGTA
(R) TGCACAGCAGACACTCATGT
6-O-sulfatase-2 (F) GGGGCAGGAACACTGTAAGA
(R) TAAACGCTGTGGCTAGGATCA
Heparanase (F) GAGCGGAGCAAACTCCGAGTGTATC
(R) GATCCAGAATTTGACCGTTCAGTTGG
ICAM-1 (F) GTCGAAGGTGGTTCTTCTGAGC
(R) TCCGTCTGCAGGTCATCTTAGG
GAPDH (F) AGAAACCTGCCAAGTATGATGAC
(R) TCATTGTCATACCAGGAAATGAG
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Corporation, Tokyo, Japan) in PBS overnight at 41C. Wells
were blocked with PBS/gelatin (BD Biosciences, Alphen a/d Rijn,
The Netherlands) for 2 h. Cell culture supernatants were incubated
with anti-HS antibodies for 1 h in a separate plate pre-coated
with PBS/gelatin. In addition, different amounts of HS from
bovine kidney were incubated with the same anti-HS antibodies to
prepare individual standard curves. The HS-coated plate was
washed with PBS/Tween and the anti-HS antibodies preincubated
with cell culture supernatants or HS from bovine kidney were
added and incubated for 1 h. Subsequently, wells were washed with
PBS/Tween and anti-HS antibody binding was detected by
incubating with the appropriate horseradish peroxidase-conjugated
antibody for 1 h. Finally, the plates were washed with PBS/
Tween and incubated with tetramethylbenzidine (TMB) solution
(SFRI Laboratories, Berganton, France). After 15 min, the reaction
was stopped with 2 M H2SO4 and absorption was measured at
450 nm.
GAG preparations and determination of GAG content
GAG preparations included HS from bovine kidney (Seikagaku
Corporation), heparosan (K5), O-sulfated heparosan, CS, and
hyaluronic acid (all from Sigma-Aldrich). Modified heparinoids
were kindly provided by Drs Van Dedem (Diosynth, Oss, The
Netherlands) and Casu (G Ronzoni Institute, Milan, Italy) and
included 2-O-desulfated heparin, 6-O-desulfated heparin, N-desul-
fated heparin, and O-desulfated heparin (Figure 4). LMW heparins
used are listed in Table 5. The amount of sulfated HS in cell culture
supernatants was determined by the Farndale assay.56
Static adhesion assay
mGEnC-1 was cultured in 96-well plates until confluence. 32Dcl3
cells, primary granulocytes, or WEHI 274.1 cells (6 105 cells ml1)
were labeled with calcein-AM (25 mg ml1; Invitrogen) in PBS for
30 min, washed in PBS, and resuspended in medium. Standard
curves of adhesion of different numbers of labeled leukocytes to
mGEnC-1 were always included. In general, 60 000 labeled
leukocytes were added in one well and incubated for 30 min at
371C. Where indicated, mGEnC-1, 32Dcl3 cells, primary granulo-
cytes, or WEHI 274.1 cells were treated by GAG-degrading enzymes
or preincubated with GAGs/heparinoids or anti-HS antibodies.
After incubation, plates were filled with medium and centrifuged
upside down for 5 min at 300 g, this was repeated once, subsequently
cells were lyzed in 50 mM Tris (pH 8.3) with 0.1% SDS and
fluorescence was measured.
Adhesion experiments under dynamic flow conditions
Adhesion of 32Dcl3 granulocyte cells to mGEnC-1 was measured
under flow conditions exactly as described.47 The 32Dcl3 cells
were perfused over TNF-a-activated mGEnC-1 at a shear stress
rate of 0.8 dyne cm2 for 60 s with a recording of 10 images s1.
The effect of the anti-HS antibodies EW3D10 and AO4B08
(25mg ml1) on the average number of rolling and firmly adhering
32Dcl3 cells, and on the average rolling velocity was determined. All
experiments were performed in duplicate in three independent
experiments.
Statistical Analysis
Values are expressed as means7s.e.m. and significance was
evaluated by Mann–Whitney U test using GraphPad Prism, version
4.0 software (GraphPad Software Inc., San Diego, CA, USA).
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SUPPLEMENTARY MATERIAL
Figure S1. Expression of different HS domains by unstimulated and
IL-1b-activated mGEnC-1 and the involvement of NF-kB.
Figure S2. Release of HS in cell culture supernatant by unstimulated
and IL-1b-activated mGEnC-1.
Figure S3. HS plays an important role during adhesion of 32Dcl3 cells
to IL-1b-activated mGEnC-1.
Figure S4. Inhibitory effect of released HS on adhesion of 32Dcl3
cells to IL-1b-activated mGEnC-1.
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